IP Library Granted Patent US 9,012,503
Granted Patent B2
US 9,012,503 · App. 13/377,867 · Granted Apr 21, 2015

Ophthalmic composition

Inventors: Nobuhito Tabuchi (Tokyo, JP); Chieko Inoue (Tokyo, JP); Manabu Hattori (Tokyo, JP); Miyuki Miyake (Tokyo, JP); Hazuki Tsutsui (Tokyo, JP)
Assignee: Lion Corporation
A61K31/203A61K9/0048A61K31/22A61K31/23A61K9/08A61K47/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,012,503
App. No.
13/377,867
Granted
Apr 21, 2015
Kind
B2
Abstract

Disclosed is an ophthalmic composition containing (A) not less than 50,000 units/100 mL of vitamin A, (B) not less than 0.4 W/V % of a polyoxyethylene polyoxypropylene glycol, and (C) trometamol.

Claims (18)

1. An ophthalmic composition comprising

(A) 50,000 to 500,000 units/100 mL of vitamin A,

(B) 0.4 to 5 W/V % of polyoxyethylene polyoxypropylene glycol, and

(C) trometamol,

wherein a ratio being expressed as [(A) vitamin A units/100 mL]/[(B) polyoxyethylene polyoxypropylene glycol g/100 mL] is 10,000 to 150,000.

2. The ophthalmic composition as defined in claim 1 , wherein a content of the ingredient (A) is at least 100,000 units/100 mL.

3. The ophthalmic composition as defined in claim 1 , wherein a content of the ingredient (A) is at least 200,000 units/100 mL.

4. The ophthalmic composition as defined in claim 1 , wherein a content of the ingredient (A) is at least 300,000 units/100 mL.

5. The ophthalmic composition as defined in any one of claims 1 to 4 , further comprising (D) an antioxidant.

6. The ophthalmic composition as defined in claim 5 , wherein the ingredient (D) is vitamin E and/or dibutylhydroxytoluene.

7. The ophthalmic composition as recited in claim 1 , wherein the ingredient (A) is retinol palmitate, retinol acetate or retinoic acid.

8. The ophthalmic composition as defined in claim 1 , wherein a ratio by weight between the ingredient (B) and the ingredient (C) expressed as (B):(C) is at 1:30 to 30:1.

9. The ophthalmic composition as defined in claim 1 , wherein a ratio by weight between the ingredient (B) and the ingredient (C), the weight ratio being expressed as (B):(C), is at 1:5 to 20:1.

10. The ophthalmic composition as recited in claim 1 , wherein the polyoxyethylene in the polyoxyethylene polyoxypropylene glycol ingredient (B) has an average degree of polymerization of ethylene oxide of 20 to 200 and wherein the polyoxypropylene in the polyoxyethylene polyoxypropylene glycol ingredient (B) has an average degree of polymerization of propylene oxide of 20 to 70.

11. The ophthalmic composition as defined in claim 1 , wherein a content of trometamol ingredient (C) is 0.1 to 3 W/V % relative to the total amount of the ophthalmic composition.

12. The ophthalmic composition as defined in claim 1 , further comprising as an antioxidant ingredient (D) d-α-tocopherol.

13. The ophthalmic composition as defined in claim 1 , further comprising as an antioxidant ingredient (D) a combination of vitamin E and dibutylhydroxytoluene.

14. The ophthalmic composition as defined in claim 1 , which is obtained by solubilizing (A) vitamin A in sterilized purified water with the aid of (B) polyoxyethylene polyoxypropylene glycol, followed by adding (C) trometamol.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2011
From: TABUCHI, NOBUHITO; INOUE, CHIEKO; HATTORI, MANABU; MIYAKE, MIYUKI; TSUTSUI, HAZUKI
To: LION CORPORATION
Reel/Frame 027382/0084 →
Continuity (1)
Related Publication 20120095097A1 · Apr 19, 2012